# A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers

> **NCT05040880** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 46 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmione plus 80/12.5mg
- **DRUG:** Micardis plus 80/12.5mg

## Key facts

- **NCT ID:** NCT05040880
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040880, "A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05040880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*